Zenosense,
a healthcare technology company involved in developing and marketing devices to
detect MRSA and signs of lung cancer in exhaled breath, has announced the
completion of protocol design of a significant lung cancer detection trial.
Testing will done in a clinical setting and is subject to agreements with a
compatible hospital in the near future.
The aim of
the trial is to test the ability of a prototype Zenosense lung cancer detector,
currently under development. Clinical tests will divide a total of 400 patients
into four groups; smokers, non-smokers, lung cancer patients and those
diagnosed with Chronic Obstructive Pulmonary Disease.
There is
extensive scientific data which indicates that lung cancer causes alterations
in cellular metabolism, due to oxidative stress, resulting in the production of
a number of distinctive Volatile Organic Compounds in exhaled breath. The trial
looks to identify the lung cancer biomarkers and to determine the adequacy of
the Device in detecting these biomarkers, compared to conventional laboratory
analysis.
Breath
samples will be taken from each subject using a standard breath sampler. They
will be captured, stored and analyzed to a strict protocol taking into account
ambient air samples. These samples will be analyzed in parallel by conventional
laboratory methods including Gas Chromatography (“GC”) and Mass Spectrometry
(“MS”); and by two prototype devices of the same design, to ensure device
results are copied.
Zenosense
is a detection device development company based in Valencia, Spain. ZENO
endeavors to develop medical devices targeting the early detection of both
deadly bacteria and certain cancers in the exhaled breath of patients. Further,
the company looks to market and sell these products to hospitals and primary
healthcare facilities. The two devices currently under development are a device
intended to detect the Methicillin-resistant Staphylococcus aureus “Super-Bug”
(MRSA) and a device intended to detect Lung Cancer. Using a common Electronic
Nose technology platform, the devices analyze Volatile Organic Compounds
(VOCs), which are present in the exhaled breath of patients, scanning for
certain biomarkers which can indicate the presence of infection/illness.
For more
information on the company, visit www.zenosense.net
About QualityStocks
QualityStocks
is committed to connecting subscribers with companies that have huge potential
to succeed in the short and long-term future. We offer several ways for
investors to find, evaluate, and learn more about investing in these companies.
Sign up
for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The
Quality Stocks Daily Blog http://blog.qualitystocks.net
The
Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The
Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
No comments:
Post a Comment